Skip to content
Pill with imprint ZA47, white, capsule, 18 mm (Divalproex Sodium 250 mg)

“Divalproex Sodium Extended-Release Tablets USP, 250 mg are available as white to off-white, capsule-shaped, biconvex, film-coated tablets imprinted with "ZA47" on one side and the other side plain”

ZA47 pill

Pill with imprint ZA47 is white, capsule, 18 mm and has been identified as Divalproex Sodium 250 mg. It is used for depression and bipolar disorder. It is supplied by Coupler LLC.

Divalproex Sodium 250 mg

Imprint
ZA47
Strength
250 mg
Used for
Depression and bipolar disorder
Color
White
Shape
Capsule / oblong
Size
18 mm
Score
No score line
Form
Tablet, film coated, extended release
Manufacturer
Coupler LLC
NDC
67046-1137, 68001-105, 67046-1137-3, 68001-105-00, 68001-105-03, 68084-310, 68084-310-11, 68084-310-01

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Divalproex Sodium pills and guides

What is Divalproex Sodium used for?

Divalproex Sodium is used for depression and bipolar disorder.

Official uses from the US prescribing label

Mania

Divalproex sodium extended-release tablets are a valproate and are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. A mixed episode is characterized by the criteria for a manic episode in conjunction with those for a major depressive episode (depressed mood, loss of interest or pleasure in nearly all activities).

The efficacy of divalproex sodium extended-release tablets are based in part on studies of divalproex sodium delayed-release tablets in this indication, and was confirmed in a 3-week trial with patients meeting DSM-IV TR criteria for bipolar I disorder, manic or mixed type, who were hospitalized for acute mania.

The effectiveness of valproate for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. Therefore, healthcare providers who elect to use divalproex sodium extended-release tablets for extended periods should continually reevaluate the long-term risk-benefits of the drug for the individual patient.

Epilepsy

Divalproex sodium extended-release tablets are indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with complex partial seizures that occur either in isolation or in association with other types of seizures. Divalproex sodium extended-release tablets are also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures in adults and children 10 years of age or older, and adjunctively in adults and children 10 years of age or older with multiple seizure types that include absence seizures.

Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present.

Migraine

Divalproex sodium extended-release tablets are indicated for prophylaxis of migraine headaches. There is no evidence that divalproex sodium extended-release tablets are useful in the acute treatment of migraine headaches.

Important Limitations

Because of the risk to the fetus of decreased IQ, neurodevelopmental disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable.

For prophylaxis of migraine headaches, divalproex sodium extended-release tablets are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception.

From the FDA-approved label on DailyMed (published Oct 05, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows ZA47 and the other side is plain.
  • It is white, capsule, 18 mm.
  • The score line, coating and any logo match the photo.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Divalproex Sodium

Inactive: Hydroxypropyl Cellulose (1600000 Wamw), Hypromellose, Unspecified, Lecithin, Soybean, Magnesium Stearate, Polyethylene Glycol, Unspecified, Polyvinyl Alcohol, Unspecified, Silicon Dioxide, Talc, Titanium Dioxide, Xanthan Gum

Also distributed by

Bluepoint Laboratories, American Health Packaging

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Divalproex Sodium pills